The current epidemiology of diabetes in children in China shows that in addition to the increasing number of children with type 1 diabetes, the prevalence of type 2 diabetes in children is also gradually increasing, so due to the special physical conditions of children, the requirements for the treatment of drugs are relatively special and safer. However, many glucose-lowering drugs have not yet been approved for use in children’s glucose-lowering treatment. Therefore, insulin is still the main glucose-lowering treatment for children, and insulin analogues, relatively speaking, have a longer effective action time and more stable effect, which can better avoid the occurrence of hypoglycemia. At present, the insulin analogues approved for use in children through clinical research in China are: 1. long-acting insulin (Chinese SFDA approved for use in children aged ≥ 6 years) 2. short-acting insulin (Chinese SFDA approved for use in children aged ≥ 2 years). Clinically, the application of insulin analogues in children still needs to be selected with care.